Dechra Pharmaceuticals plc (LON:DPH) has received an average rating of “Buy” from the eight analysts that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is GBX 2,121.17 ($29.31).
A number of research firms have recently weighed in on DPH. Numis Securities reissued an “add” rating and issued a GBX 2,640 ($36.47) price objective on shares of Dechra Pharmaceuticals in a research report on Friday, February 2nd. Royal Bank of Canada lowered shares of Dechra Pharmaceuticals to a “sector performer” rating and boosted their price objective for the company from GBX 2,200 ($30.40) to GBX 2,400 ($33.16) in a research report on Thursday, February 1st. Finally, Jefferies Group raised shares of Dechra Pharmaceuticals to a “buy” rating and boosted their price objective for the company from GBX 2,221 ($30.69) to GBX 2,631 ($36.35) in a research report on Tuesday, January 30th.
Dechra Pharmaceuticals (LON DPH) remained flat at $GBX 2,250 ($31.09) during trading hours on Friday. 161,610 shares of the company traded hands, compared to its average volume of 203,836. The firm has a market cap of $2,300.00 and a price-to-earnings ratio of 8,035.71. Dechra Pharmaceuticals has a 52-week low of GBX 1,530 ($21.14) and a 52-week high of GBX 2,458 ($33.96).
Dechra Pharmaceuticals Company Profile
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.